|
Cerebricon is the world’s premier contract research organization (CRO) in the area of specialized and focused preclinical models for CNS and PNS. Cerebricon preclinical models include models for neurology, psychiatry, biomarkers and biomedical imaging. All models are performed in Cerebricon’s proprietal laboratories by its permanent staff of scientists and technicians. Cerebricon’s preclinical platform includes in vivo small animal models, in vitro cell culture models, behavioural laboratories, small animal imaging (MRI) services, radiolabelling and SPECT as well as histology and immunohistochemistry services. Preclinical in vivo modelsCerebricon’s fully validated preclinical models include preclinical surgical models and mouse transgenic models for neurology:
All routes of administration have been validated for ip, sc, po, im, iv, ic, intrathecal, intranasal, osmotic minipumps, diets and drinking water. Preclinical behavioural, functional and cognitive modelsEither alone or in conjunction with the above in vivo assays, Cerebricon’s staff of behavioural scientists and technicians has fully validated preclinical behavioural models for neurology and psychiatry. Cerebricon has preclinical models for cognition, preclinical models for function and preclinical models for behaviour for naïve rats and mice, and aged rats and aged mice. Cerebricon also has transgenic disease models and surgical and chemically induced preclinical models. Tests for cognition:
Sensory motor tests:
Anxiety and depression:
Behavioural phenotyping:
Preclinical imaging and radiolabelling servicesCerebricon has its own 7.0 Tesla small animal MRI. Cerebricon uses this to employ the following techniques for the preclinical study of compounds aimed at CNS and PNS diseases and also biomarkers:
Cerebricon also employs SPECT scanning and routinely carries out radiolabelling for client compounds. Preclinical in vitro modelsCerebricon’s in vitro laboratories perform rodent primary cell culture models and provide high throughput screening of compounds for neurotoxicity, neuroprotection and neurite outgrowth (NOG). In addition, more comprehensive and concentrated studies of compound mechanism of action are regularly performed in our in vitro laboratories.
Cultures can be exposed to glutamate, NMDA, kainate, oxygen glucose deprivation (OGD), H2O2, Aß (beta amyloid), LPS, KCL and 6-OHDA. Cerebricon also has in-house histology and immunohistochemistry services.
Cerebricon Ltd
Microkatu 1 Kuopio 70211 Finland Contact: Business Development Tel: +358 17 3680 801 Fax: +358 17 3680 803 Email: info@cerebricon.com URL: www.cerebricon.com URL: www.cerebricon.com/D...%20Paper%2004-08.pdf |
Cerebricon has its own scientists, preclinical laboratories and animal facilities for CNS drug development; this includes a 7.0 Tesla MRI for small animal imaging including pharmacological MRI (phMRI) for use with in vivo, in vitro and ex vivo models of CNS and PNS disease. Pharmacological MRI (phMRI) is a new method used for the noninvasive preclinical study of drugs aimed at CNS diseases like Alzheimer’s, Parkinson’s and stroke; it is also used for the study of psychiatric diseases. Here we see the in vivo signal created by the iv introduction of nicotine by a specific area in the cortex of the brain. Cerebricon’s laboratories are fully equipped to run multiple studies in parallel, while Cerebricon’s internal quality assurance programme ensures that studies and results adhere to the highest possible standards; where possible Cerebricon studies are automated. Cerebricon can run preclinical rodent studies with small numbers of animals all the way up to very large cohorts. The ability of a CNS CRO to provide behavioural modelling and the most pertinent transgenic model, as well as imaging and histological services all under one roof, is very important. Here we see a close up of amyloid beta plaques from the hippocampus of a transgenic (TG2576) mouse; this was done with immunohistochemical detection in Cerebricon’s laboratories. |